A Study of Bortezomib as Consolidation Therapy in Patients With Multiple Myeloma
Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is determination of the event-free survival with and without
Bortezomib consolidation therapy from the day of the first chemotherapeutic, myeloma-specific
therapy measure, up to the occurrence of progression/recurrence or up to the occurrence of
death.